35 U.S.C. § 101

35 U.S.C. § 101

35 U.S.C. § 101 is the United States statutory provision defining patent-eligible subject matter, establishing that whoever invents or discovers a new and useful process, machine, manufacture, or composition of matter may obtain a patent. The statute sits within Title 35 of the United States Code and has been the focal point of extensive litigation involving the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, United States Patent and Trademark Office, and major technology companies such as IBM, Microsoft, Google, Apple Inc., and Amazon (company). Its application affects industries represented by entities like Pfizer, Genentech, Merck & Co., Intel, Qualcomm, Tesla, Inc., and institutions such as Massachusetts Institute of Technology, Stanford University, Harvard University, and Johns Hopkins University.

Background and Statutory Text

The statute traces its statutory placement to the Patent Act of 1952, enacted by the United States Congress and signed under the administration of Dwight D. Eisenhower. The statutory text provides the categorical list—process, machine, manufacture, composition of matter—that has been interpreted against prior statutes including the Patent Act of 1790 and legislative history discussed in proceedings of committees such as the House Committee on the Judiciary and the Senate Judiciary Committee. The provision interacts with other codified sections including 35 U.S.C. § 102 and 35 U.S.C. § 103 and is applied alongside regulatory guidance from the United States Patent and Trademark Office and administrative precedent from the Patent Trial and Appeal Board.

Judicial Interpretation and Key Supreme Court Decisions

Judicial interpretation has been shaped by leading cases from the Supreme Court of the United States including Diamond v. Chakrabarty, Gottschalk v. Benson, Parker v. Flook, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Alice Corp. v. CLS Bank International, and Bilski v. Kappos. Decisions such as Diamond v. Chakrabarty and Diamond v. Diehr affirmed patent eligibility for biotechnology and applied processes involving Genentech and DuPont, while Mayo and Alice Corp. v. CLS Bank International introduced and refined the two-step framework later echoed by panels of the United States Court of Appeals for the Federal Circuit in cases involving parties like DDR Holdings, LLC and Enfish LLC. The Supreme Court’s jurisprudence has prompted commentary from legal scholars at institutions including Yale Law School, Columbia Law School, University of Chicago Law School, and advocacy from organizations such as the American Intellectual Property Law Association.

Patentable Subject Matter Doctrine and Exceptions

Courts have articulated exceptions to patentable subject matter for laws of nature, natural phenomena, and abstract ideas—concepts central to rulings involving Mayo Collaborative Services, Alice Corp., and Association for Molecular Pathology v. Myriad Genetics, Inc.. The Myriad Genetics decision addressed patentability of isolated DNA sequences in litigation involving Myriad Genetics and research institutions like University of Utah. Debates reference scientific actors such as James Watson, Francis Crick, and companies like Illumina and Roche due to implications for genomics, diagnostics, and biotechnology. The doctrine has implications for financial technologies litigated by firms including Goldman Sachs and Citigroup, and for software systems developed by Oracle Corporation, SAP SE, and Adobe Inc..

Application in Patent Prosecution and Examination

In practice, patent examiners at the United States Patent and Trademark Office apply guidance from the Manual of Patent Examining Procedure and follow precedents from the Federal Circuit and Supreme Court of the United States when assessing claims from applicants including universities, startups, and corporations such as Google, Amazon (company), IBM, and biotechnology firms like Amgen. Examiners use procedures involving 35 U.S.C. § 101 rejections, interview practices recommended by the American Bar Association, and appeal routes through the Patent Trial and Appeal Board and United States Court of Appeals for the Federal Circuit. The outcome of eligibility assessments affects licensing negotiations involving firms such as BlackBerry Limited, Nokia, Ericsson, and standard-setting bodies including Institute of Electrical and Electronics Engineers and World Intellectual Property Organization stakeholders.

Criticisms, Policy Debates, and Reform Proposals

The statute and its judicial gloss have generated policy debates led by lawmakers from the United States Senate and the United States House of Representatives, with reform proposals discussed in hearings before the Senate Judiciary Committee and testimony from industry groups such as the Biotechnology Innovation Organization and the Computer & Communications Industry Association. Critics include academics from Stanford Law School and Harvard Law School and companies like Apple Inc. and Facebook, Inc. which have advocated for clarifying legislation to address uncertainty highlighted in Alice Corp. v. CLS Bank International and Mayo Collaborative Services. Legislative proposals and model statutes have been advanced by think tanks such as the Brookings Institution and Heritage Foundation, and international comparisons look to frameworks in the European Patent Office, Japan Patent Office, and World Trade Organization agreements to inform potential amendments.

Category:United States patent law